Description: Abeona Therapeutics, Inc., formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for severe and rare diseases. The Company's lead program includes adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB). Its product pipeline includes ABO-101 (sc AAV9 NAGLU), which is used for the treatment of MPS III B; ABO-102 (sc AAV9 SGSH), which is used for the treatment of MPS III A; ABO-201 (sc AAV9 CLN3), which is used for the treatment of Juvenile Batten Disease (JBD); ABO-301 (AAV LK19 FANCC), which is used for the treatment of Fanconi Anemia (FA), and clustered, regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) gene editing, which is used for treatment of other rare blood diseases. The Company offers two platforms: Salt Diafiltration (SDF) Process and Polymer Hydrogel Technology (PHT).
Home Page: www.abeonatherapeutics.com
ABEO Technical Analysis
1330 Avenue of the Americas
New York,
NY
10019
United States
Phone:
646 813 4701
Officers
| Name | Title |
|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | Pres, CEO & Director |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Sr. VP & Gen. Counsel |
| Mr. Joseph Walter Vazzano | Chief Financial Officer |
| Mr. Brian Kevany Ph.D. | VP, CTO & Head of Research |
| Mr. Gregory Gin | VP of Investor Relations & Corp. Communications |
| Scott Santiamo | Director of Corp. Communications |
| Ms. Alison Hardgrove | VP of HR |
| Mr. Jon Voss | VP & Head of Quality |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.0786 |
| Price-to-Book MRQ: | 3.3097 |
| Price-to-Sales TTM: | 10.7102 |
| IPO Date: | 1980-09-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 90 |